Search

Your search keyword '"Zivanovic, Oliver"' showing total 786 results
Start Over Author "Zivanovic, Oliver"
786 results on '"Zivanovic, Oliver"'

6. Bridging Communication Gaps Between Radiologists, Referring Physicians, and Patients Through Standardized Structured Cancer Imaging Reporting: The Experience with Female Pelvic MRI Assessment Using O-RADS and a Simulated Cohort Patient Group

Author

Woo, Sungmin, Andrieu, Pamela Causa, Abu-Rustum, Nadeem R., Broach, Vance, Zivanovic, Oliver, Sonoda, Yukio, Chi, Dennis S., Aviki, Emeline, Ellis, Annie, Carayon, Pascale, Hricak, Hedvig, and Vargas, Hebert A.

Published
2024
Full Text
View/download PDF

12. Impact of postoperative morbidity on outcomes in patients with advanced epithelial ovarian cancer undergoing intestinal surgery at the time of primary or interval cytoreductive surgery: A Memorial Sloan Kettering Cancer Center Team Ovary study

Author

Praiss, Aaron M., Hirani, Rahim, Zhou, Qin, Iasonos, Alexia, Sonoda, Yukio, Abu-Rustum, Nadeem R., Leitao, Mario M., Jr, Long Roche, Kara, Broach, Vance, Gardner, Ginger J., Chi, Dennis S., and Zivanovic, Oliver

Published
2023
Full Text
View/download PDF

13. GOG 244 - The Lymphedema and Gynecologic cancer (LeG) study: The impact of lower-extremity lymphedema on quality of life, psychological adjustment, physical disability, and function

Author

Carter, Jeanne, Huang, Helen Q, Armer, Jane, Carlson, Jay W, Lockwood, Suzy, Nolte, Susan, Kauderer, James, Hutson, Alan, Walker, Joan L, Fleury, Aimee C, Bonebrake, Albert, Soper, John T, Mathews, Cara, Zivanovic, Oliver, Richards, William Edward, Tan, Annie, Alberts, David S, Barakat, Richard R, and Wenzel, Lari B

Subjects
Prevention, Clinical Trials and Supportive Activities, Patient Safety, Rehabilitation, Clinical Research, Uterine Cancer, Cancer, Cervical Cancer, Management of diseases and conditions, 7.1 Individual care needs, Adult, Aged, Aged, 80 and over, Female, Genital Neoplasms, Female, Humans, Leg, Lymphedema, Middle Aged, Postoperative Complications, Prospective Studies, Quality of Life, Quality of life, Endometrial cancer, Cervical cancer, Vulvar cancer, GOG 244, Oncology and Carcinogenesis, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis
Abstract

ObjectiveTo assess quality of life (QOL) in patients who developed lower-extremity lymphedema (LLE) after radical gynecologic cancer surgery on prospective clinical trial GOG 244.MethodsThe prospective, national, cooperative group trial GOG-0244 determined the incidence of LLE and risk factors for LLE development, as well as associated impacts on QOL, in newly diagnosed patients undergoing surgery for endometrial, cervical, or vulvar cancer from 6/4/2012-11/17/2014. Patient-reported outcome (PRO) measures of QOL (by the Functional Assessment of Cancer Therapy [FACT]), body image, sexual and vaginal function, limb function, and cancer distress were recorded at baseline (within 14 days before surgery), and at 6, 12, 18, and 24 months after surgery. Assessments of LLE symptoms and disability were completed at the time of lower limb volume measurement. A linear mixed model was applied to examine the association of PROs/QOL with a Gynecologic Cancer Lymphedema Questionnaire (GCLQ) total score incremental change ≥4 (indicative of increased LLE symptoms) from baseline, a formal diagnosis of LLE (per the GCLQ), and limb volume change (LVC) ≥10%.ResultsIn 768 evaluable patients, those with a GCLQ score change ≥4 from baseline had significantly worse QOL (p

Published
2021

16. Leave it in the past - primary treatment modality for high-grade epithelial ovarian cancer is not associated with secondary cytoreduction outcomes: A Memorial Sloan Kettering Cancer Center Team Ovary study

Author

Sia, Tiffany Y., Manning-Geist, Beryl L., Ehmann, Sarah, Lavery, Jessica A., Luardo, Carrie, Praiss, Aaron, Iasonos, Alexia, Sonoda, Yukio, Grisham, Rachel N., Liu, Ying L., Broach, Vance, Zivanovic, Oliver, Long Roche, Kara, Gardner, Ginger J., and Chi, Dennis S.

Published
2023
Full Text
View/download PDF

17. Patient-reported symptoms after minimally invasive hysterectomy and association with postoperative complications

Author

Feinberg, Jacqueline, Zivanovic, Oliver, Hannon, Michael, McCready, Taylor, Desai, Priyanka, Kim, Sarah H., Aviki, Emeline M., Mueller, Jennifer J., Jewell, Elizabeth L., Long Roche, Kara, Gardner, Ginger J., Chi, Dennis S., Sonoda, Yukio, Brown, Carol L., Abu-Rustum, Nadeem R., Cracchiolo, Jennifer R., Leitao, Mario M., Jr, and Broach, Vance

Published
2023
Full Text
View/download PDF

18. Robotic Surgery in the Frail Elderly: Analysis of Perioperative Outcomes

Author

Aloisi, Alessia, Tseng, Jill, Kuhn, Theresa, Feinberg, Jacqueline, Chi, Dennis S, Brown, Carol L, Mueller, Jennifer J, Gardner, Ginger J, Zivanovic, Oliver, Jewell, Elizabeth L, Long Roche, Kara, Broach, Vance, Abu-Rustum, Nadeem R, and Leitao, Mario M

Subjects
Aging, Cardiovascular, Clinical Research, Patient Safety, Prevention, Management of diseases and conditions, 7.1 Individual care needs, Good Health and Well Being, Aged, Female, Frail Elderly, Frailty, Gynecologic Surgical Procedures, Humans, Neoplasms, Patient Readmission, Postoperative Complications, Risk Factors, Robotic Surgical Procedures, Treatment Outcome, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeThe frail are considered at higher risk for unfavorable surgical outcomes (major complications/mortality). We assessed the safety of and outcomes associated with robotic surgery in the frail elderly undergoing gynecologic procedures.MethodsWe identified patients aged ≥ 65 years who underwent a robotic procedure between May 2007 and December 2016. Frailty was defined as the presence of at least three of five frailty factors-more than five comorbidities, low physical activity, weight loss, exhaustion, and fatigue. Perioperative outcomes were recorded. We compared variables among frail and non-frail patients and performed a multivariate logistic regression to detect variables associated with major complications (≥ grade 3) or 90-day mortality.ResultsWe identified 982 patients: 71 frail and 911 non-frail patients. Median age was 71 years. Median BMI was 29.8 kg/m2. Thirty-four patients (3.5%) had a 30-day readmission. Seventy-seven (7.8%) had a postoperative complication, of which 23 (2.3%) were major. Ninety-day mortality was 0.5%. There were significant differences with regard to age (P

Published
2020

19. GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients

Author

Carlson, Jay W, Kauderer, James, Hutson, Alan, Carter, Jeanne, Armer, Jane, Lockwood, Suzy, Nolte, Susan, Stewart, Bob R, Wenzel, Lari, Walker, Joan, Fleury, Aimee, Bonebrake, Albert, Soper, John, Mathews, Cara, Zivanovic, Oliver, Richards, Wm Edward, Tan, Annie, Alberts, David S, and Barakat, Richard R

Subjects
Clinical Research, Cancer, Cervical Cancer, Uterine Cancer, Prevention, Patient Safety, Adult, Aged, Aged, 80 and over, Female, Genital Neoplasms, Female, Humans, Incidence, Leg, Lymph Node Excision, Lymphedema, Middle Aged, Prospective Studies, Regression Analysis, Risk Factors, Endometrial cancer, Vulvar cancer, Cervical cancer, Lymphadenectomy, Staging, Oncology and Carcinogenesis, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis
Abstract

ObjectivesTo evaluate the incidence and risk factors for lymphedema associated with surgery for gynecologic malignancies on GOG study 244.MethodsWomen undergoing a lymph node dissection for endometrial, cervical, or vulvar cancer were eligible for enrollment. Leg volume was calculated from measurements at 10-cm intervals starting 10 cm above the bottom of the heel to the inguinal crease. Measurements were obtained preoperatively and postoperatively at 4-6 weeks, and at 3-, 6-, 9-, 12-, 18-, and 24- months. Lymphedema was defined as a limb volume change (LVC) ≥10% from baseline and categorized as mild: 10-19% LVC; moderate: 20-40% LVC; or severe: >40% LVC. Risk factors associated with lymphedema were also analyzed.ResultsOf 1054 women enrolled on study, 140 were inevaluable due to inadequate measurements or eligibility criteria. This left 734 endometrial, 138 cervical, and 42 vulvar patients evaluable for LVC assessment. Median age was 61 years (range, 28-91) in the endometrial, 44 years (range, 25-83) in the cervical, and 58 years (range, 35-88) in the vulvar group. The incidence of LVC ≥10% was 34% (n = 247), 35% (n = 48), and 43% (n = 18), respectively. The peak incidence of lymphedema was at the 4-6 week assessment. Logistic regression analysis showed a decreased risk with advanced age (p = 0.0467). An exploratory analysis in the endometrial cohort showed an increased risk with a node count >8 (p = 0.033).ConclusionsFor a gynecologic cancer, LVC decreased with age greater than 65, but increased with a lymph node count greater than 8 in the endometrial cohort. There was no association with radiation or other risk factors.

Published
2020

20. Morbidity after secondary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for ovarian cancer: An analysis of a randomized phase II trial

Author

Praiss, Aaron M., Zhou, Qin, Iasonos, Alexia, Moukarzel, Lea, Dessources, Kimberly, Soldan, Krysten, Su, Katy, Sonoda, Yukio, Long Roche, Kara, Gardner, Ginger J., Troso-Sandoval, Tiffany, Tew, William P., Grisham, Rachel N., Chi, Dennis S., O'Cearbhaill, Roisin E., and Zivanovic, Oliver

Published
2023
Full Text
View/download PDF

21. Ovarian cancer mutational processes drive site-specific immune evasion

Author

Vázquez-García, Ignacio, Uhlitz, Florian, Ceglia, Nicholas, Lim, Jamie L. P., Wu, Michelle, Mohibullah, Neeman, Niyazov, Juliana, Ruiz, Arvin Eric B., Boehm, Kevin M., Bojilova, Viktoria, Fong, Christopher J., Funnell, Tyler, Grewal, Diljot, Havasov, Eliyahu, Leung, Samantha, Pasha, Arfath, Patel, Druv M., Pourmaleki, Maryam, Rusk, Nicole, Shi, Hongyu, Vanguri, Rami, Williams, Marc J., Zhang, Allen W., Broach, Vance, Chi, Dennis S., Da Cruz Paula, Arnaud, Gardner, Ginger J., Kim, Sarah H., Lennon, Matthew, Long Roche, Kara, Sonoda, Yukio, Zivanovic, Oliver, Kundra, Ritika, Viale, Agnes, Derakhshan, Fatemeh N., Geneslaw, Luke, Issa Bhaloo, Shirin, Maroldi, Ana, Nunez, Rahelly, Pareja, Fresia, Stylianou, Anthe, Vahdatinia, Mahsa, Bykov, Yonina, Grisham, Rachel N., Liu, Ying L., Lakhman, Yulia, Nikolovski, Ines, Kelly, Daniel, Gao, Jianjiong, Schietinger, Andrea, Hollmann, Travis J., Bakhoum, Samuel F., Soslow, Robert A., Ellenson, Lora H., Abu-Rustum, Nadeem R., Aghajanian, Carol, Friedman, Claire F., McPherson, Andrew, Weigelt, Britta, Zamarin, Dmitriy, and Shah, Sohrab P.

Published
2022
Full Text
View/download PDF

22. Contributors

Author

Aviki, Emeline, primary, Berkowitz, Ross S., additional, Broach, Vance, additional, Cantrell, Leigh A., additional, Chui, M. Herman, additional, Cliby, William, additional, Elias, Kevin M., additional, Hedrick Ellenson, Lora, additional, Fader, Amanda N., additional, Filho, Donato Callegaro, additional, Fleming, Nicole D., additional, Frumovitz, Michael, additional, Gershenson, David M., additional, Gordhandas, Sushmita, additional, Grisham, Rachel N., additional, Herbst, Arthur, additional, Hillman, R. Tyler, additional, Hinchcliff, Emily, additional, Hodgson, Anjelica, additional, Horowitz, Neil S., additional, Kertowidjojo, Elizabeth, additional, Kim, Sarah H., additional, Knisely, Anne, additional, Kurnit, Katherine C., additional, Lawson, Barrett, additional, Leitao, Mario M., additional, Levine, Douglas A., additional, Liu, Ying, additional, Long, Beverly, additional, Manning-Geist, Beryl, additional, Miao, Diana, additional, Mueller, Jennifer J., additional, Nagarajan, Priyadharsini, additional, O’Cearbhaill, Roisin E., additional, Peng, Katherine, additional, Ramalingam, Preetha, additional, Ratan, Ravin, additional, Salvo, Gloria, additional, Santin, Alessandro D., additional, Shafer, Aaron, additional, Soliman, Pamela, additional, Somasegar, Sahana, additional, Tymon-Rosario, Joan R., additional, Wright, Jason D., additional, Yamada, S. Diane, additional, and Zivanovic, Oliver, additional

Published
2023
Full Text
View/download PDF

24. Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level – A Memorial Sloan Kettering Cancer Center study

Author

Kahn, Ryan M., McMinn, Erin, Yeoshoua, Effi, Boerner, Thomas, Zhou, Qin, Iasonos, Alexia, Long Roche, Kara, Zivanovic, Oliver, Gardner, Ginger J., Sonoda, Yukio, O'Cearbhaill, Roisin E., Grisham, Rachel N., Tew, William, Jones, David, Huang, James, Park, Bernard J., Abu-Rustum, Nadeem R., and Chi, Dennis S.

Published
2023
Full Text
View/download PDF

25. Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management

Author

Liu, Ying L., Manning-Geist, Beryl L., Knezevic, Andrea, Deng, Luxue, Bromberg, Maria, Funt, Samuel A., Meisel, Jane L., Zivanovic, Oliver, Long Roche, Kara, Sonoda, Yukio, Gardner, Ginger J., Grisham, Rachel N., O'Cearbhaill, Roisin E., Tew, William P., Abu-Rustum, Nadeem R., Chi, Dennis S., Aghajanian, Carol, and Feldman, Darren R.

Published
2023
Full Text
View/download PDF

30. GOG 244 - The LymphEdema and Gynecologic cancer (LEG) study: The association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lymphedema of the lower extremity (LLE)

Author

Carter, Jeanne, Huang, Helen Q, Armer, Jane, Carlson, Jay W, Lockwood, Suzy, Nolte, Susan, Stewart, Bob R, Kauderer, James, Hutson, Alan, Walker, Joan L, Fleury, Aimee C, Bonebrake, Albert, Soper, John T, Mathews, Cara, Zivanovic, Oliver, Richards, William Edwards, Tan, Annie, Alberts, David S, Barakat, Richard R, and Wenzel, Lari

Subjects
Clinical Research, Cervical Cancer, Uterine Cancer, Cancer, Adult, Aged, Aged, 80 and over, Female, Genital Neoplasms, Female, Gynecologic Surgical Procedures, Humans, Leg, Lymphedema, Middle Aged, Self Report, Surveys and Questionnaires, Endometrial cancer, Vulvar cancer, Cervical cancer, Gynecologic cancer lymphedema questionnaire, GCLQ, Oncology and Carcinogenesis, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis
Abstract

ObjectiveTo explore whether patient-reported lymphedema-related symptoms, as measured by the Gynecologic Cancer Lymphedema Questionnaire (GCLQ), are associated with a patient-reported diagnosis of lymphedema of the lower extremity (LLE) and limb volume change (LVC) in patients who have undergone radical surgery, including lymphadenectomy, for endometrial, cervical, or vulvar cancer on Gynecologic Oncology Group (GOG) study 244.MethodsPatients completed the baseline and at least one post-surgery GCLQ and LVC assessment. The 20-item GCLQ measures seven symptom clusters-aching, heaviness, infection-related, numbness, physical functioning, general swelling, and limb swelling. LLE was defined as a patient self-reported LLE diagnosis on the GCLQ. LVC was measured by volume calculations based on circumferential measurements. A linear mixed model was fitted for change in symptom cluster scores and GCLQ total score and adjusted for disease sites and assessment time.ResultsOf 987 eligible patients, 894 were evaluable (endometrial, 719; cervical, 136; vulvar, 39). Of these, 14% reported an LLE diagnosis (endometrial, 11%; cervical, 18%; vulvar, 38%). Significantly more patients diagnosed versus not diagnosed with LLE reported ≥4-point increase from baseline on the GCLQ total score (p 10% was significantly associated with reported general swelling (p

Published
2019

32. Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues

Author

Moukarzel, Lea A., Ferrando, Lorenzo, Dopeso, Higinio, Stylianou, Anthe, Basili, Thais, Pareja, Fresia, Da Cruz Paula, Arnaud, Zoppoli, Gabriele, Abu-Rustum, Nadeem R., Reis-Filho, Jorge S., Long Roche, Kara, Tew, William P., Chi, Dennis S., Sonoda, Yukio, Zamarin, Dmitriy, Aghajanian, Carol, O'Cearbhaill, Roisin E., Zivanovic, Oliver, and Weigelt, Britta

Published
2022
Full Text
View/download PDF

35. It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer

Author

Zivanovic, Oliver, Chi, Dennis S, Filippova, Olga, Randall, Leslie M, Bristow, Robert E, and O'Cearbhaill, Roisin E

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Research, Clinical Trials and Supportive Activities, Patient Safety, Cancer, Orphan Drug, Rare Diseases, Ovarian Cancer, Female, Humans, Hyperthermia, Induced, Ovarian Neoplasms, Retrospective Studies, Hyperthermic intraperitoneal chemotherapy, HIPEC, Ovarian cancer, Debulking surgery, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Reproductive medicine
Abstract

The peritoneal spread of ovarian cancer makes it a potential target for hyperthermic intraperitoneal chemotherapy (HIPEC). Intraperitoneal delivery exposes the tumor to concentrations of cytotoxic drugs much greater than with intravenous delivery, and in vitro studies have also shown that combining hyperthermia and platinum leads to an additive cytotoxic effect. Pharmacokinetic analyses have confirmed very high concentrations of cytotoxic drugs in the peritoneal cavity, with minimal systemic exposure and toxicity. The majority of historical data evaluating HIPEC in ovarian cancer are based on retrospective research, which included heterogeneous groups of patients and drugs used for HIPEC. Recent publications on the findings of prospective studies, including the first randomized trial in which the only difference in intervention was the addition of HIPEC with cisplatin to interval debulking surgery in stage III patients, have shown a benefit in favor of HIPEC. Yet, a recent prospective study from Korea did not find a benefit. Opponents of HIPEC have cited higher rates of complications with this approach, yet most of the serious adverse events observed are likely related to the surgery itself, and are comparable to the rates reported in studies evaluating cytoreductive surgery without HIPEC. Findings from a recent randomized controlled trial showed no delays in initiation or completion of postoperative chemotherapy in patients treated with HIPEC. A growing body of evidence is indicating that it might be time to seriously consider HIPEC as a complementary treatment at the time of cytoreductive surgery for patients with advanced-stage ovarian cancer in the setting of an experienced center. Yet, more research is needed to identify the population of patients who gain the most benefit from this therapy.

Published
2018

36. Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study

Author

Hensley, Martee L, Enserro, Danielle, Hatcher, Helen, Ottevanger, Petronella B, Krarup-Hansen, Anders, Blay, Jean-Yves, Fisher, Cyril, Moxley, Katherine M, Lele, Shashikant B, Lea, Jayanthi S, Tewari, Krishnansu S, Thaker, Premal H, Zivanovic, Oliver, O'Malley, David M, Robison, Katina, and Miller, David S

Subjects
Clinical Trials and Supportive Activities, Clinical Research, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeWe conducted a randomized phase III trial to determine whether adjuvant chemotherapy improves survival in women with uterine leiomyosarcoma.MethodsWomen with uterus-confined, high-grade leiomyosarcoma who were confirmed disease free by imaging were randomly assigned to four cycles of gemcitabine plus docetaxel, followed by four cycles of doxorubicin, or to observation. All were followed for evidence of recurrence. The primary end point was overall survival (OS).ResultsWith international collaboration, 38 of the targeted accrual of 216 patients were enrolled, after which the study was closed by the National Cancer Institute for accrual futility. Twenty patients were assigned to chemotherapy, 18 to observation. Among the 17 patients treated with at least one cycle of chemotherapy, grade 3 or 4 toxicities were observed in 47%; among the 18 patients assigned to observation, one had grade 3 hypertension. There were six deaths (chemotherapy, n = 5; observation, n = 1), all due to disease. The restricted mean survival time for OS was estimated as 34.3 months (95% CI, 25.3 to 43.3 months) in the chemotherapy arm and as 46.4 months (95% CI, 43.6 to 49.1 months) in the observation arm. There were eight recurrences in each arm. The restricted mean survival time for recurrence-free survival was estimated as 18.1 (95% CI, 14.2 to 22.0) months in the chemotherapy arm and as 14.6 months (95% CI, 10.3 to 19.0 months) in the observation arm. Neither survival outcome comparison was considered statistically robust, due to the small sample size.ConclusionDespite international collaboration to test the role of adjuvant chemotherapy in uterine-confined leiomyosarcoma, this study was closed for accrual futility. Although the sample size precludes robust statistical comparison, observed OS and recurrence-free survival data do not show superior outcomes with adjuvant chemotherapy.

Published
2018

39. Germline Pathogenic Variants and Genetic Counseling by Ancestry in Patients With Epithelial Ovarian Cancer

Author

Sia, Tiffany Y., Maio, Anna, Kemel, Yelena M., Arora, Kanika S., Gordhandas, Sushmita B., Kahn, Ryan M., Salo-Mullen, Erin E., Sheehan, Margaret A., Tejada, Prince Rainier, Bandlamudi, Chaitanya, Zhou, Qin, Iasonos, Alexia, Grisham, Rachel N., OʼCearbhaill, Roisin E., Tew, William P., Roche, Kara Long, Zivanovic, Oliver, Sonoda, Yukio, Gardner, Ginger J., Chi, Dennis S., Latham, Alicia J., Carlo, Maria I., Murciano-Goroff, Yonina R., Will, Marie, Walsh, Michael F., Robson, Mark E., Mandelker, Diana L., Berger, Michael F., Abu-Rustum, Nadeem R., Brown, Carol L., Offit, Kenneth, Hamilton, Jada G., Aghajanian, Carol, Weigelt, Britta, Stadler, Zsofia K., and Liu, Ying L.

Published
2023
Full Text
View/download PDF

43. Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study

Author

L, Phuong, Piedmonte, Marion, Han, Paul K, Moser, Richard P, Walker, Joan L, Rodriguez, Gustavo, Boggess, John, Rutherford, Thomas J, Zivanovic, Oliver, Cohn, David E, Thigpen, J Tate, Wenham, Robert M, Friedlander, Michael L, Hamilton, Chad A, Bakkum-Gamez, Jamie, Olawaiye, Alexander B, Hensley, Martee L, Greene, Mark H, Huang, Helen Q, and Wenzel, Lari

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Trials and Supportive Activities, Clinical Research, Ovarian Cancer, Behavioral and Social Science, Women's Health, Prevention, Aging, Rare Diseases, Genetic Testing, Genetics, Good Health and Well Being, Adult, Age Factors, Aged, Choice Behavior, Cohort Studies, Early Detection of Cancer, Educational Status, Female, Genes, BRCA1, Genes, BRCA2, Genetic Predisposition to Disease, Humans, Middle Aged, Multivariate Analysis, Mutation, Ovarian Neoplasms, Ovariectomy, Perception, Prophylactic Surgical Procedures, Prospective Studies, Quality of Life, Risk, Risk Reduction Behavior, Salpingectomy, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Reproductive medicine
Abstract

ObjectivesWomen at increased genetic risk of ovarian cancer (OC) are recommended to have risk-reducing salpingo-oophorectomy (RRSO) after completion of reproductive planning. Effective screening has not been established, and novel screening modalities are being evaluated.MethodsParticipants chose either RRSO or a novel OC screening regimen (OCS) as their risk management option, and provided demographic and other data on BRCA mutation status, cancer worry, perceived intervention risks/benefits, perceived cancer risk, and quality-of-life at enrollment. We performed univariate and multivariate analyses to evaluate factors influencing decision between RRSO and OCS.ResultsOf 2287 participants enrolled, 904 (40%) chose RRSO and 1383 (60%) chose OCS. Compared with participants choosing OCS, participants choosing RRSO were older (p50%, both higher than objective risk estimates.ConclusionsCancer worry, BRCA1/2 mutation status, and perceived intervention-related risks and benefits were associated with choosing between RRSO and OCS. Efforts to promote individualized, evidence-based, shared medical decision-making among high-risk women facing management choices should focus on conveying accurate OC risk estimates, clarifying the current understanding of intervention-related benefits and limitations, and addressing OC worry.

Published
2017

44. Exploring the clinical significance of serous tubal intraepithelial carcinoma associated with advanced high-grade serous ovarian cancer: A Memorial Sloan Kettering Team Ovary Study

Author

Boerner, Thomas, Walch, Henry S., Nguyen, Bastien, Iasonos, Alexia, Zhou, Qin C., Schultz, Nikolaus, Chui, M. Herman, Grisham, Rachel N., Tew, William P., O'Cearbhaill, Roisin E., Aghajanian, Carol, Zivanovic, Oliver, Abu-Rustum, Nadeem R., Gardner, Ginger J., Sonoda, Yukio, Chi, Dennis S., and Long Roche, Kara

Published
2021
Full Text
View/download PDF

46. Survival outcomes of acute normovolemic hemodilution in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center Team Ovary study

Author

Boerner, Thomas, Tanner, Edward, Filippova, Olga, Zhou, Qin C., Iasonos, Alexia, Tew, William P., O'Cearbhaill, Roisin E., Grisham, Rachel N., Gardner, Ginger J., Sonoda, Yukio, Abu-Rustum, Nadeem R., Zivanovic, Oliver, Long Roche, Kara, Afonso, Anoushka M., Fischer, Mary, and Chi, Dennis S.

Published
2021
Full Text
View/download PDF

49. ARIA II: a randomized controlled trial of near-infrared Angiography during RectosIgmoid resection and Anastomosis in women with ovarian cancer.

Author

Leitao Jr, Mario M., Iasonos, Alexia, Tomberlin, Morgan, Moukarzel, Lea A., Price, Hannah, Bennetti, Gabrielle, Ramesh, Bhavani, Chi, Dennis S., Roche, Kara Long, Yukio Sonoda, Al-Niami, Ahmed, Mueller, Jennifer J., Gardner, Ginger J., Broach, Vance, Jewell, Elizabeth L., Kim, Sarah, Feinberg, Jacqueline, Abu-Rustum, Nadeem R., and Zivanovic, Oliver

Published
2024
Full Text
View/download PDF

50. A pre-operative scoring model to estimate the risk of blood transfusion over an ovarian cancer debulking surgery (BLOODS score): a Memorial Sloan Kettering Cancer Center Team Ovary study.

Author

Kahn, Ryan M., Boerner, Thomas, Kim, Michael, Lam, Clarissa, Gordhandas, Sushmita, Yeoshoua, Effi, Zhou, Qin C., Iasonos, Alexia, Al-Niaimi, Ahmed, Gardner, Ginger J., Roche, Kara Long, Sonoda, Yukio, Zivanovic, Oliver, Grisham, Rachel N., Abu-Rustum, Nadeem R., and Chi, Dennis S.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results